Sugi Predict

Sugi Predict / Targets / GPR6

GPR6

G-protein coupled receptor 6 · P46095 · GPR6 on Sugi Atlas →

22,461 patent compounds predicted against GPR6, 7,539 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL227505 SCHEMBL227505 0.48 19/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2775952) 0.48 19/20
SCHEMBL227139 SCHEMBL227139 0.58 18/20
SCHEMBL2264590 SCHEMBL2264590 0.47 16/20
SCHEMBL2470340 SCHEMBL2470340 0.45 13/20
SCHEMBL2223981 SCHEMBL2223981 0.48 12/20
SCHEMBL2271128 SCHEMBL2271128 0.47 11/20
SCHEMBL2223990 SCHEMBL2223990 0.46 11/20
SCHEMBL2271014 SCHEMBL2271014 0.42 11/20
SCHEMBL2224409 SCHEMBL2224409 0.48 10/20
SCHEMBL2224144 SCHEMBL2224144 0.48 9/20
SCHEMBL2269616 SCHEMBL2269616 0.48 9/20
SCHEMBL2222799 SCHEMBL2222799 0.45 9/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL1938242) 0.39 9/20
SCHEMBL2543078 SCHEMBL2543078 0.38 9/20
SCHEMBL2008069 SCHEMBL2008069 0.36 9/20
SCHEMBL1899893 SCHEMBL1899893 0.51 8/20
SCHEMBL2225548 SCHEMBL2225548 0.46 8/20
SCHEMBL2031369 SCHEMBL2031369 0.46 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2555357) 0.45 8/20

Clinical trials — most relevant to GPR6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus PHASE2/PHASE3UNKNOWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans. nanCOMPLETED
Gastroparesis Registry 3 nanCOMPLETED
Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6 nanCOMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance nanUNKNOWN
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients nanCOMPLETED
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis nanUNKNOWN
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis nanCOMPLETED
IL-6 Regulation of Substrate Metabolism and Influence of Obesity nanCOMPLETED
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis nanWITHDRAWN
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers nanCOMPLETED
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome nanACTIVE_NOT_RECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Short-Term Application of Tocilizumab Following Myocardial Infarction nanCOMPLETED
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity nanNOT_YET_RECRUITING
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling nanCOMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms nanCOMPLETED
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors nanUNKNOWN
Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GPR6 binder may also engage these)

ProteinNameSimilarity
P51651 — 1.000 P51651 →
Q6YNI2 — 0.997 Q6YNI2 →
GPR3 G-protein coupled receptor 3 0.982 landscape →
P35413 — 0.981 P35413 →
Q8K1Q3 — 0.981 Q8K1Q3 →
Q9BZJ8 — 0.959 Q9BZJ8 →
Q8C010 — 0.956 Q8C010 →
MLNR Motilin receptor 0.950 landscape →
Q9NS66 — 0.950 Q9NS66 →
Q8NDV2 — 0.950 Q8NDV2 →
Q9JJH2 — 0.949 Q9JJH2 →
Q6PI62 — 0.947 Q6PI62 →
S1PR5 Sphingosine 1-phosphate receptor 5 0.946 landscape →
Q9JKM5 — 0.946 Q9JKM5 →
Q5E9H8 — 0.946 Q5E9H8 →
GPR27 Probable G-protein coupled receptor 27 0.945 landscape →
P60894 — 0.945 P60894 →
Q9BGL8 — 0.944 Q9BGL8 →
Q8BZA7 — 0.944 Q8BZA7 →
Q91X56 — 0.944 Q91X56 →
P60893 — 0.943 P60893 →
PTGER1 Prostaglandin E2 receptor EP1 subtype 0.943 landscape →
Q9QXI3 — 0.941 Q9QXI3 →
O54897 — 0.941 O54897 →
P60895 — 0.940 P60895 →
Q9H1Y3 — 0.940 Q9H1Y3 →
Q5RBG7 — 0.939 Q5RBG7 →
Q9I919 — 0.939 Q9I919 →
P35375 — 0.939 P35375 →
CNR2 Cannabinoid receptor 2 0.939 landscape →